Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 12/20 | 0.58 |
| ▸ | IDO1 | P14902 | 2/20 | 0.43 |
| ▸ | AGXT | P21549 | 2/20 | 0.43 |
| ▸ | APP | P05067 | 3/20 | 0.39 |
| ▸ | CTSL | P07711 | 1/20 | 0.39 |
| ▸ | CTSB | P07858 | 1/20 | 0.39 |
| ▸ | CTSK | P43235 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14734271 | 0.90 | NAAA (0.54) | NAAAIDO1AGXT | |
| SCHEMBL16685900 | 0.84 | NAAA (0.51) | NAAAIDO1AGXTAPP | |
| SCHEMBL22397634 | 0.80 | CTSL (0.58) | NAAACTSLCTSBCTSK | |
| SCHEMBL3049370 | 0.79 | NAAA (0.43) | NAAAIDO1AGXTAPPCTSL | |
| SCHEMBL16654046 | 0.78 | NAAA (0.54) | NAAAIDO1AGXTAPP | |
| SCHEMBL17279144 | 0.78 | NAAA (0.62) | NAAACTSLCTSBCTSK | |
| SCHEMBL18764205 | 0.78 | NAAA (0.62) | NAAACTSLCTSBCTSK | |
| SCHEMBL17279137 | 0.78 | NAAA (0.62) | NAAACTSLCTSBCTSK | |
| SCHEMBL16654121 | 0.78 | NAAA (0.54) | NAAAIDO1AGXTAPP | |
| SCHEMBL16685531 | 0.76 | NAAA (0.49) | NAAAIDO1AGXTAPP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2747769-B1 | 2-SPIRO-SUBSTITUTED IMINOTHIAZINES AND THEIR MONO-AND DIOXIDES AS BACE INHIBITORS, COMPOSITIONS AND THEIR USE | MERCK SHARP & DOHME (US) | 2017-08-02 | — | — | EP | disclosed |
| US-9181236-B2 | 2-spiro-substituted iminothiazines and their mono-and dioxides as bace inhibitors, compositions and their use | MERCK SHARP & DOHME CORP. (US) | 2015-11-10 | — | — | US | disclosed |
| US-20140200213-A1 | 2-SPIRO-SUBSTITUTED IMINOTHIAZINES AND THEIR MONO-AND DIOXIDES AS BACE INHIBITORS, COMPOSITIONS AND THEIR USE | MERCK SHARP & DOHME CORP. (US) | 2014-07-17 | — | — | US | disclosed |
| WO-2013028670-A1 | 2-SPIRO-SUBSTITUTED IMINOTHIAZINES AND THEIR MONO-AND DIOXIDES AS BACE INHIBITORS, COMPOSITIONS AND THEIR USE | MERCK SHARP & DOHME CORP. (US) | 2013-02-28 | — | — | WO | disclosed |
| US-20100222317-A1 | Azetidine Derivatives as GlyT1 Inhibitors | MERCK SHARP & DOHME LIMITED (GB) | 2010-09-02 | — | — | US | disclosed |
| US-20100222317-A1 | Azetidine Derivatives as GlyT1 Inhibitors | MERCK SHARP & DOHME LIMITED (GB) | 2010-09-02 | — | — | US | disclosed |
| EP-1960360-A1 | AZETIDINE DERIVATIVES AS GLYT1 INHIBITORS | MERCK SHARP & DOHME LTD. (GB) | 2008-08-27 | — | — | EP | disclosed |
| WO-2007060484-A1 | AZETIDINE DERIVATIVES AS GLYT1 INHIBITORS | MERCK SHARP & DOHME LIMITED (GB) | 2007-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222317-A1 | Azetidine Derivatives as GlyT1 Inhibitors | GRIA1, GLRA1, GRIN1 | NAAA 2004/4885IDO1 243/4885AGXT 92/4885 |
| US-20140200213-A1 | 2-SPIRO-SUBSTITUTED IMINOTHIAZINES AND THEIR MONO-AND DIOXIDES AS BACE INHIBITORS, COMPOSITIONS AND THEIR USE | BACE2, BACE1, APP | NAAA 3935/4885IDO1 979/4885AGXT 3281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.